Thomas Lars Andresen

Thomas Lars Andresen

Auto-generated profile, based on publicly available information

Thomas Lars Andresen

Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Molecular Therapy
Verified
Journal Article
Open access
RBRikke V Benjaminsen
Rikke V Benjaminsen
MMMaria A Mattebjerg
Maria A Mattebjerg
JHJonas R Henriksen
Jonas R Henriksen
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
TAThomas L Andresen
Thomas L Andresen
Polycations such as polyethylenimine (PEI) are used in many novel nonviral vector designs and there are continuous efforts to increase our mechanistic understanding of their interactions with cells. Even so, the mechanism of polyplex escape from the endosomal/lysosomal pathway after internalization is still elusive. The “proton sponge ” hypothesis remains the most generally accepted mechanism, although it is heavily debated. This hypothesis is associated with the large buffering capacity of PEI and other polycations, which has been interpreted to cause an increase in lysosomal pH even though no conclusive proof has been provided. In the present study, we have used a nanoparticle pH sensor that was developed for pH measurements in the endosomal/lysosomal pathway. We have carried out quantitative measurements of lysosomal pH as a function of PEI content and correlate the results to the “proton sponge ” hypothesis. Our measurements show that PEI does not induce change in lysosomal pH as previously suggested and quantification of PEI concentrations in lysosomes makes it uncertain that the “proton sponge ” effect is the dominant mechanism of polyplex escape.

1 January 2005 in Progress in Lipid Research
Verified
Journal Article
Closed access
TAThomas L. Andresen
Thomas L. Andresen
SJSimon S. Jensen
Simon S. Jensen
KJKent Jørgensen
Kent Jørgensen

10 February 2012 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
AHA.C. Hunter
A.C. Hunter
TAT.L. Andresen
T.L. Andresen
Intravenously injected nanoparticulate drug carriers provide a wide range of unique opportunities for site-specific targeting of therapeutic agents to many areas within the vasculature and beyond. Pharmacokinetics and biodistribution of these carriers are controlled by a complex array of interrelated core and interfacial physicochemical and biological factors. Pertinent to realizing therapeutic goals, definitive maps that establish the interdependency of nanoparticle size, shape, and surface characteristics in relation to interfacial forces, biodistribution, controlled drug release, excretion, and adverse effects must be outlined. These concepts are critically evaluated and an integrated perspective is provided on the basis of the recent application of nanoscience approaches to nanocarrier design and engineering. The future of this exciting field is bright; some regulatory-approved products are already on the market and many are in late-phase clinical trials. With concomitant advances in extensive computational knowledge of the genomics and epigenomics of interindividual variations in drug responses, the boundaries toward development of personalized nanomedicines can be pushed further.

1 February 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
KKKristina Bram Knudsen
Kristina Bram Knudsen
HNHelle Northeved
Helle Northeved
PEPramod Kumar Ek
Pramod Kumar Ek
APAnders Permin
Anders Permin
TGTorben Gjetting
Torben Gjetting
MRMartin Roursgaard
Martin Roursgaard
This study investigated toxicity of nanocarriers comprised of cationic polymer and lipid components often used in gene and drug delivery, formulated as cationic micelles and liposomes. Rats were injected intravenously with 10, 25 or 100 mg/kg and sacrificed after 24 or 48 h, or 24 h after the last of three intravenous injections of 100 mg/kg every other day. Histological evaluation of liver, lung and spleen, clinical chemistry parameters, and hematology indicated little effect of treatment. DNA strand breaks were increased in the lung and spleen. Further, in the dose response study we found unaltered expression levels of genes in the antioxidant response (HMOX1) and repair of oxidized nucleobases (OGG1), whereas expression levels of cytokines (IL6, CXCL2 and CCL2) were elevated in lung, spleen or liver. The results indicate that assessment of genotoxicity and gene expression add information on toxicity of nanocarriers, which is not obtained by histology and hematology. This study investigates the toxicity of cationic micelles and liposomes utilized as nanocarriers in gene and drug delivery, demonstrating its effects on the lungs, spleen and liver.

1 January 2019 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
KJKasper Bendix Johnsen
Kasper Bendix Johnsen
JGJohann Mar Gudbergsson
Johann Mar Gudbergsson
TAThomas Lars Andresen
Thomas Lars Andresen
JSJens Bæk Simonsen
Jens Bæk Simonsen
Circulating biomarkers have a great potential in diagnosing cancer diseases at early stages, where curative treatment is a realistic possibility. In the recent years, using extracellular vesicles (EVs) derived from blood as biomarkers has gained widespread popularity, mainly because they are thought to be easy to isolate and carry a vast variety of biological cargos that can be analyzed for biomarker purposes. However, our current knowledge on the plasma EV concentration in normophysiological states is sparse. Here, we provide the very first mean estimate of the plasma EV concentration based on values obtained from a thorough literature review. The different estimates obtained from the literature are correlated to the isolation techniques used to obtain them, illustrating how some methodologies may over- or underestimate the plasma EV concentration. We also show that the estimated plasma EV concentration (approximately 1010 EVs per mL) defines EVs as a minority population compared to other colloidal particles of the systemic circulation, namely the lipoproteins, which are known contaminants in EV isolates and carry biomarker molecules themselves. Lastly, we introduce the possibility of regarding EVs and lipoproteins as a continuum of lipid-containing particles to which biomarker molecules can be associated. Using such a holistic approach, increased strength of plasma-derived cancer biomarkers may soon be revealed.

29 May 2015 in ACS Nano
Verified
Journal Article
Closed access
AHAnders E. Hansen
Anders E. Hansen
APAnncatrine L. Petersen
Anncatrine L. Petersen
JHJonas R. Henriksen
Jonas R. Henriksen
BBBetina Boerresen
Betina Boerresen
PRPalle Rasmussen
Palle Rasmussen
TAThomas L. Andresen
Thomas L. Andresen